More than a quarter of patients with generalized myasthenia gravis (gMG) spend more than a year waiting for an accurate diagnosis, according to a survey-based study conducted across five European countries. Study findings also suggested that patients who waited more than one year to be diagnosed might have…
Kyverna Therapeutics’ experimental cell therapy, KYV-101, has been granted regenerative medicine advanced therapy (RMAT) status by the U.S. Food and Drug Administration (FDA) for treating progressive myasthenia gravis (MG). RMAT designation is intended to expedite the development and FDA review of experimental regenerative treatments that treat, modify, reverse,…
Patients with generalized myasthenia gravis (gMG) with mild pre-surgery muscle weakness had more favorable outcomes after a thymectomy, which involves the surgical removal of the thymus gland, than those with moderate or severe muscle weakness, a study finds. In their study, “Pre-thymectomy disease severity predicts outcome in…
Remegen enrolled the first U.S. patient in a Phase 3 trial testing the safety and efficacy of telitacicept to treat generalized myasthenia gravis (gMG), according to a company press release, This Phase 3 clinical trial (NCT06456580) is a global, multi-center, randomized, double-blind, placebo-controlled study in which…
An under-the-skin, or subcutaneous, injectable form of efgartigimod alfa has been approved in China to treat adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor. The therapy was approved as an add-on to standard gMG treatment. This subcutaneous formulation of efgartigimod (efgartigimod…
Get regular updates to your inbox.